Enveric Biosciences Past Earnings Performance

Past criteria checks 0/6

Enveric Biosciences's earnings have been declining at an average annual rate of -19.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.

Key information

-19.4%

Earnings growth rate

21.2%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth raten/a
Return on equity-249.5%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Enveric Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:SLZA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1053
30 Jun 240-1164
31 Mar 240-1586
31 Dec 230-1797
30 Sep 230-23108
30 Jun 230-23138
31 Mar 230-19128
31 Dec 220-19128
30 Sep 220-52189
30 Jun 220-52168
31 Mar 220-50167
31 Dec 210-49205
30 Sep 210-11142
30 Jun 210-9131
31 Mar 210-9110
31 Dec 200-750
30 Sep 200-320
30 Jun 200-320
31 Mar 200-330
31 Dec 190-220
30 Sep 190-330
31 Dec 180-220

Quality Earnings: SLZA is currently unprofitable.

Growing Profit Margin: SLZA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SLZA is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.

Accelerating Growth: Unable to compare SLZA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLZA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Return on Equity

High ROE: SLZA has a negative Return on Equity (-249.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies